Prosecution Insights
Last updated: August 17, 2026

Examiner: HIRAKIS, SOPHIA P

Tech Center 1600 • Art Units: 1623

This examiner grants 52% of resolved cases

Performance Statistics

52.2%
Allow Rate
-7.8% vs TC avg
90
Total Applications
+73.3%
Interview Lift
1335
Avg Prosecution Days
Based on 46 resolved cases, 2023–2026

Rejection Statute Breakdown

1.7%
§101 Eligibility
14.5%
§102 Novelty
35.0%
§103 Obviousness
33.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18557258 Use of Terpenoids and Salicylates as Anesthetics and Analgesics Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18026330 LIGHT-CONTROLLED BIOORTHOGONAL TETRAZINE LIGATION Non-Final OA The Regents of the University Of California
18032067 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER Final Rejection Bayer Aktiengesellschaft
18412178 EGCG buccal tablet and use thereof Non-Final OA Hainan Aoruikang Biomedical Technology Co., Ltd
17641668 BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION Non-Final OA HSIRI THERAPEUTICS, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month